NCT01136408 - A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin | Biotech Hunter

Enrollment

174

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

September 30, 2006

Conditions

Atrial Fibrillation

Interventions

DRUG

Dabigatran etexilate

Dabigatran etexilate 110 mg capsule, twice a day, oral administration

DRUG

Dabigatran etexilate

Dabigatran etexilate 150 mg capsule, twice a day, oral administration

DRUG

Warfarin

Dose-adjusted warfarin based on target INR values

Trial Locations (28)

Unknown

1160.49.024 Boehringer Ingelheim Investigational Site, Aki-gun, Hiroshima

1160.49.025 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka

1160.49.026 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka

1160.49.021 Boehringer Ingelheim Investigational Site, Himeji, Hyogo

1160.49.027 Boehringer Ingelheim Investigational Site, Iizuka,Fukuoka

1160.49.013 Boehringer Ingelheim Investigational Site, Kyoto, Kyoto

1160.49.011 Boehringer Ingelheim Investigational Site, Nagoya, Aichi

1160.49.012 Boehringer Ingelheim Investigational Site, Nagoya, Aichi

1160.49.004 Boehringer Ingelheim Investigational Site, Naka-gun, Ibaragi

1160.49.022 Boehringer Ingelheim Investigational Site, Okayama, Okayama

1160.49.023 Boehringer Ingelheim Investigational Site, Okayama, Okayama

1160.49.006 Boehringer Ingelheim Investigational Site, Oota, Tokyo

1160.49.016 Boehringer Ingelheim Investigational Site, Osaka, Osaka

1160.49.017 Boehringer Ingelheim Investigational Site, Osaka, Osaka

1160.49.018 Boehringer Ingelheim Investigational Site, Osaka, Osaka

1160.49.019 Boehringer Ingelheim Investigational Site, Osaka, Osaka

1160.49.020 Boehringer Ingelheim Investigational Site, Sakai, Osaka

1160.49.001 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

1160.49.028 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

1160.49.002 Boehringer Ingelheim Investigational Site, Sendai, Miyagi

1160.49.005 Boehringer Ingelheim Investigational Site, Shinjuku, Tokyo

1160.49.014 Boehringer Ingelheim Investigational Site, Suita, Osaka

1160.49.015 Boehringer Ingelheim Investigational Site, Suita, Osaka

1160.49.007 Boehringer Ingelheim Investigational Site, Tokorozawa, Saitama

1160.49.009 Boehringer Ingelheim Investigational Site, Toyama, Toyama

1160.49.003 Boehringer Ingelheim Investigational Site, Tsuchiura, Ibaragi

1160.49.029 Nagano National Hospital, Ueda, Nagano

1160.49.008 Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa